Focus is marketing a product, this has a much quicker regulatory path.
I will gladly take any dividends however would rather see market launch/collaborations/partnership/buyout with share appreciation.
1.NR2F6--->Applicatble to canine/feline cancer. This is what C. Ichim brought to the party.
Dr. Ichim stated, "I am extremely excited about having the opportunity to apply my knowledge of cancer stem cells to treating leukemia in cats and cancer in dogs...7/16/14.
"The findings of novel candidate sequences to improve gene silencing of NR2F6 is a fundamental advancement in our work towards biologically treating cancer," said Dr. Thomas Ichim, Chief Scientific Officer...1/8/15.
"NR2F6 (EAR-2) is a novel leukemia and MDS oncogene, over-expressed in patients, that inhibits hematopoietic differentiation and blocks erythropoietic differentiation at the proerythrocyte stage.....5/5/15.
